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Abstracts of invited papers
Eukaryotic cell cycle control
S. Moreno, R. Bartlett, S. Sazer & P. Nurse
Microbiology Unit, Department ofBiochemistry, University of
Oxford, South Parks Road, Oxford OX] 3QU, UK.
There are two main points of control during the eukaryotic
cell cycle, one acting in GI for onset of S and a second
acting in G2 for onset of mitosis. In broad outline the latter
control is now understood at least in part, and involves the
p34CdC2 protein kinase which becomes activated during mito-
sis. A genetical approach for investigating the transition from
mitosis through GI into S-phase in the simple eukaryote
fission yeast will be described. Two gene functions are requir-
ed for proper exit of mitosis, cndlt which encodes a DNA
methyl cytosine transferase and dcdlt which encodes an
RCCI like protein. A new gene rumlt has been discovered
which regulates onset of S-phase. Over-producing rumlt
locks the cell in a replicating state leading to nuclei ofgreatly
increased ploidy. This regulation operates through the start
control which commits cells to the cell cycle and involves the
p34cdc2 protein kinase and the p85cdclo transcription factor.
Oncogenes, cell cycle and antineoplastic drugs
G.F. Vande Woude, N. Shulz, R. Zhou, W. Matten, K.
Fukasawa, N. Yew & M. Oskarrson
ABL-Basic Research Program, NCI-Frederick Cancer Research
and Development Center, Frederick, MD 21702, USA.
The mos proto-oncogene product, pp39mos, is required for
meiotic maturation in vertebrate oocytes and is an active
component of cytostatic factor (CSF), an activity that is
responsible for arrest of meiosis at metaphase II. CSF is
thought to arrest egg development at M-phase by stabilising
M-phase promoting factor (MPF). Thus, the mos product
functions at a major cell cycle control point, and its activity
is directly or indirectly responsible for the stabilisation of
MPF. This direct link between proto-oncogene function and
M-phase cell cycle regulation could be responsible for certain
phenotypes of mos transformed cells.
The Associations gratefully acknowledge support given to the
meeting by the following: Cancer Research Campaign, Imperial
Cancer Research Fund, Biometra Limited, Cambridge Bioscience,
Ciba Geigy Pharmaceuticals, Dynal (UK) Limited, Jeol (UK)
Limited, Life Technologies Limited, Promega Limited, Sera-Lab
Limited, Sigma Chemical Co. Limited, Stratagene Limited,
Wisepress Limited.
We have found that mos product is associated with and
phosphorylates tubulin in vitro. Our analyses have also
shown that 1B-tubulin is preferentially associated with and
phosphorylated by the Xenopus mos product prepared from
either transformed cells or unfertilised eggs. Immunofluo-
rescence and immunoelectron microscopy analyses have
shown that the mos product in transformed cells colocalises
with tubulin in microtubules as well as in the metaphase
spindle and early telophase mid-body and asters. We specu-
late that the mos product may contribute to the formation of
the spindle pole as well as the spindle and thereby contribute
(as CSF) to metaphase arrest.
Constitutive expression of mos in somatic cells is responsi-
ble for morphological transformation. Only cells expressing
low levels of pp39mos can grow as transformed cells. We
postulate that this amount of product is not sufficient to
cause mitotic arrest but is enough to impart M-phase pheno-
types during interphase. Altered cell morphology and loss of
contact inhibition during interphase could be due to cyto-
skeletal changes that normally occur during mitosis. Further-
more, the transformed phenotype may be mediated through
M-phase modification of interphase microtubules by pp39mOs.
Checkpoint genes, as first described by Weinert and Hartwell,
function as pauses in the cell cycle to allow the fidelity of the
process to be checked. We have proposed that oncogenes
with downstream M-phase activity, compromise cell cycle
checkpoint functions. This could be responsible for the
genetic instability of tumor cells as well as provide an explan-
ation for how antineoplastic drugs work. Research sponsored
by the National Cancer Institute, DHHS, under contract No.
NOI-CO-74101 with ABL.
The 1993 Gordon Hamilton-Fairley Lecture
The cell cycle regulatory functions of the retinoblastoma gene
product and its related proteins, p107 and p300
D.M. Livingstone
Dana-Farber Cancer Institute & Harvard Medical School,
Boston, Massachusetts, USA.
RB and its related proteins, p107 and p300, are nuclear
constituents which can form stable complexes with certain
transforming proteins of DNA Tumour Viruses. Proteins
such as SV40 T antigen and the Adenovirus ElA protein can
form complexes with all three proteins, and complex forma-
tion correlates strongly with the ability of these proteins to
serve their transforming functions. Moreover, from detailed
biological and in vivo and in vitro structure-function analyses
of RB, p107 and p300, it seems clear that these proteins
operate to regulate key events in the cell cycle. Binding to
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one or another viral transforming protein can block one or
more aspects of their growth controlling function. Since RB
and p107 operate, at least in part, by forming complexes with
one or more transcription factors, at least one or which,
itself, does seemingly important cell cycle work, it seems
likely that part of their control over key cell cycle switch
points is manifest by the modulation of the action of their
transcription factor targets. The potential mechanisms which
regulate the ability of RB to affect the behaviour of the
transcription factor, E2F - a major RB and p107 binding
target, to deliver a growth suppressing signal towards the end
of GI, and to modulate E2F transactivation function will be
discussed.
The retinoblastoma protein, its relatives and partners
E. Harlow, L. Cao, A. Fattaey, K. Helin, M.-H. Lee, J. Lees,
A. Tallis, M. Vidal, L. Yamasaki, L. Zhu & N. Dyson
Massachussets General Hospital Cancer Center, Building 149,
13th Street, Charlestown, MA 02129, USA.
Small DNA tumour viruses, such as adenovirus, encode pro-
teins that are potent transforming agents when tested in
standard oncogenic assays. For adenovirus the best charac-
terized viral oncoproteins are the early region lA (ElA)
products. Introducing the ElA gene into primary cells leads
to the establishment of immortal cell lines. When EIA is
introduced in conjunction with the appropriate cooperating
oncogenes, the recipient cells become fully transformed. The
regions of EIA that are required for its oncogenic potential
have been determined, and they correspond to the regions
that allow ElA to bind to a number of cellular polypeptides.
This correlation of structure and function suggests that these
cellular proteins are the targets for ElA-mediated transfor-
mation. There are 11 proteins that are known to bind either
directly or indirectly to EIA, and 4 of these proteins have
now been identified. The 105 Kd protein is the product of the
retinoblastoma tumour suppressor gene (pRB), the 107 Kd
protein (p1O7) is a relative of pRB, the 60kD protein is
cyclin A, and the 33 Kd protein is cyclin-dependent kinase 2
(cdk2), a protein closely related to the cell cycle-regulating
kinase cdc2.
Although pRB has been intensively studied in recent years,
we still know very little about its actual biochemical function.
However, we have begun to understand some of the basic
characteristics of the signal transduction pathway in which
pRB acts. The upstream regulation of pRB appears to be
controlled at least partially by protein phosphorylation. One
form of pRB is the un- or underphosphorylated species that
is found primarily in the GI phase of the cell cycle. As cells
move into late Gl and S phase, pRB is phosphorylated by a
cyclin-dependent kinase.
Only one target of pRB is well characterised and this is the
transcription factor E2F. At least for some promoters, pRB
acts as a negative regulator of transcription by binding to
E2F and holding it in an inactive state. In some circum-
stances E2F also associates with the pRB-related p107 pro-
tein. Both the pRB/E2F and plO7/E2F complexes are found
in distinct portions of the cell cycle. In the presence of ElA,
the E2F/pRB and E2F/p1O7 complexes are dissociated, and
free E2F is available to activate transcription, regardless of
the cell cycle position.
p53 in human cancer
D.P. Lane
Cancer Research Campaign Laboratories, University ofDundee,
Dundee DDI 4HN, UK.
Mutations in the p53 gene are one of the commonest specific
genetic changes found in human cancer. Germline mutations
in p53 predispose affected individuals to the early develop-
ment of a wide range of neoplasias. In mice complete 'knock
out' of the p53 gene does not prevent normal development
but the mice show an extraordinary incidence of cancer. In
normal cells p53 protein is present only in very small
amounts but the protein accumulates in response to DNA
damage. The mechanism of accumulation is post transla-
tional. This response may represent an essential cell cycle
checkpoint control, since the induction of p53 is associated
with an inhibition of cellular DNA synthesis and activation
of the transcription. Studies of cell lines from cancer families
and from mouse models suggest that the p53 protein plays a
key role in this damage checkpoint pathway but that genes
upstream and downstream of p53 act to transduce the
damage signal to p53 and to mediate the growth response
that follows p53 induction. Damage to these genes may also
be important in neoplasia. The p53 pathway seems to play an
essential role in maintaining genetic integrity. Breakdown of
this pathway may be a common step in the development of
neoplasia since it permits the survival and selection of
damaged cells. Detailed studies of the DNA binding activity
of pure p53 show that the normal protein is produced in a
cryptic form that cannot bind DNA but that modification of
the C terminal 26 amino acids of p53 can activate this latent
function. Activators include the binding of monoclonal anti-
bodies, phosphorylation by Casein kinase 2, ATP dependant
reactions with hsp70 like proteins and partial proteolysis.
This activation reaction may represent an early step in the
damage response and we are now studying in detail the
activation mechanism induced by DNA damage.
Cyclin Dl as a cellular oncogene
G. Peters, G.A. Lammie, S. Bates, I. Palmero, L. Bonetta &
C. Dickson
Imperial Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK
Deregulated expression of the cyclin Dl gene is a feature of
several types of tumour. For example, the gene is modestly
amplified in about 15% of primary human breast cancers
and squamous cell carcinomas. Although amplification leads
to over-expression, cyclin Dl is only one of several candidate
oncogenes on the > 1500 kb of DNA that is typically ampli-
fied. The evidence for a direct role is more persuasive in
parathyroid adenomas where the gene is activated by a
chromosomal rearrangement that juxtaposes the cyclin DI
and parathyroid hormone genes. In certain B-cell tumours,
particularly centrocytic lymphoma, expression of the gene is
affected by a reciprocal translocation between the BLC-J
locus on chromosome 1 1q13 and the immunoglobulin heavy
chain on 14q23. Although a considerable distance from the
breakpoint on 1 1q13, it appears that cyclin D1 is the target
oncogene for the BCL-1 translocation. Similarly, the mouse
homolog of cyclin Dl gene lies close to Fis-J, a proviral
insertion site in Friend MuLV-induced lymphomas. The
exact synteny between the corresponding regions of mouse
chromosome 7 and human chromosome 11q13 suggests that
disruption of Fis-l may be functionally analogous to the
BCL-J translocation.
To better understand the role of cyclin DI in these
tumours, we examined the expression of the gene and of its
close relatives, cyclins D2 and D3, in a variety of haema-
tological malignancies. The patterns of expression suggest
that the three genes are independently regulated but there is
considerable overlap in many cell types. To determine whether
their functions also overlap, we have prepared specific anti-
peptide sera in order to assess interactions between the cyclin
D family and other cellular proteins. Of particular interest
are potential associations with cdc2-related protein kinases,
via the conserved sequences in the so-called 'cyclin box'.
Recent data suggest that the D-type cyclins may be regula-
tory subunits for the PSK-J3/cdk4 kinase rather than cdc2 or438 JOINT WINTER MEETING REPORT
cdk2, but cyclin D immunoprecipitates contain at least two
additional proteins that react with an antibody against the
PSTAIRE motif. This multiplicity of cyclin-kinase partner-
ships will be discussed in relation to the oncogenic potential
of the D cyclins.
Interactions between HPV proteins and regulators of cell
growth
K.H. Vousden, R. Davies & T. Crook
Ludwig Institute for Cancer Research, St. Mary's Hospital
Medical School, Norfolk Place, London W2 IPG, UK.
Human papillomavirus type 16 (HPV16) infection is associ-
ated with most ano-genital cancers and two virally encoded
proteins, E6 and E7, appear to play a role in the develop-
ment and maintenance of these malignancies. Both E6 and
E7 display transforming and immortalising activities in
rodent and human cells and the mechanisms by which these
viral proteins function are related to their ability to form
complexes with host proteins normally involved in regulating
cell growth. E6 has been shown to bind and target the
tumour suppressor protein p53 for rapid degradation (Scheff-
ner et al., 1990, Cell, 63, 1129) and the importance of this
interaction in malignant development is strongly supported
by the inverse correlation between presence of HPV and
somatic p53 mutations in primary human ano-gential cancers.
These studies indicate that the loss ofwild type p53 following
E6 expression is sufficient to allow the development of a
primary cancer, although further analyses have indicated that
somatic mutation resulting in the expression of a mutant p53
protein may still play a role in the metastatic progression of
HPV positive primary cervical cancers. All of the mutant
p53s detected in ano-gential cancers acquired transforming
activities, although their ability to bind and be targeted for
degradation by E6 varied. Interestingly, p53 mutants detected
in HPV positive metastases showed some resistance to E6
mediated degradation. HPV16 E7 also interacts with a
number of cell proteins which are involved in cell cycle
regulation. In addition to the previously described interaction
with the RB protein (Dyson et al., 1989, Science, 243, 934),
we have recently shown an association of E7 with the RB
related p107 protein and a cell cycle regulated histone HI
kinase activity. Analysis ofmutant proteins has shown that a
similar region of E7 participates in each of these associations,
although subtle differences in the sequence requirements for
RB and p107 binding can be detected. Since this region of E7
is also necessary for transforming activity it seems likely that
some, or all, of these interactions are necessary for the
biological activity of the E7 protein.
Abstracts of members' proffered
papers
Session 1: Cell proliferation, cycle and death (No's 1-9)
Session 2: Suppression genes/growth factors (No's 10-18)
Session 3: Metastasis/drug therapy (No's 19-27)
1 S-phase traverse and the cytotoxicity of the DNA topo-
isomerase I poison camptothecin
S.J. Falk & P.J. Smith
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge CB2 2QH, UK.
The marked S-phase specificity of the anti-tumour type I
topoisomerase poison camptothecin (CPT) is thought to
result from the interaction of trapped enzyme molecules -
'cleavable complexes' - with replicons and the subsequent
generation of lethal DNA double strand breaks. Understand-
ing the consequences of DNA synthesis inhibition of CPT
toxicity is important for the design of combination regimens
and for understanding the basis of differential drug sensi-
tivity. This study examined the cytotoxic and cell cycle effects
of CPT and the DNA a polymerase inhibitor aphidicolin
(APC) on two SV40 transformed human fibroblast cell lines,
MRC5CVI and AT5BIVA, the latter being CPT hypersensi-
tive. Flow cytometry was used to determine cell cycle delay
and DNA synthesis patterns, whilst topoisomerase I trapping
was assessed by K+-SDS precipitation.
Clonogenic assays showed that 24 h co-treatment of cul-
tures with non-toxic concentrations (0.2-2 pg/ml) of APC
could efficiently rescue both cell lines from the cytotoxicity of
CPT. Exposure to APC alone results in a dose-related and
progressive trapping of up to 80% of the population of both
cell lines in early S phase during a 24 h exposure period, and
markedly reduces the incorporation of bromodeoxyuridine
into S phase DNA. Stathmokinetic analysis with the mitosis
blocking agent colcemid shows that some cells in mid and
late S phase can still pass into G2/M during APC treatment.
During a 24 h exposure to CPT alone there is a delay of cells
transversing S phase, the extent and duration of delay being
dose-dependent in both cell lines but not related to CPT
sensitivity. However the CPT-sensitive cell line showed
enhanced G2 arrest. Co-treatment of either cell line with
APC and CPT for up to 24 h results in the efficient trapping
of cells in early S phase with no apparent effect of CPT on
the re-entry of late S/G2 cells into GI. The ability of short
high dose treatment with CPT to introduce cross-links into
DNA was not reduced by either 24 h pre-treatment with
CPT, APC or combined treatments.
The results suggest that the toxicity-related G2 arrest
induced in both resistant and sensitive human cells by CPT,
arises as a consequence of S phase-associated events. We
conclude that hypersensitivity to CPT is due to an abnorma-
lity in handling the lesions arising from replicon collison with
trapped complexes.
2 Growth in vitro of follicular lymphoma: resistance to apop-
tosis and proliferation in the CD 40 system
P.W.M. Johnson, S.M. Watt, D.R. Betts, D. Davies &
T.A. Lister
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London, UK.
Follicular lymphoma cells were isolated from eight lymph
node biopsy specimens by immunomagnetic depletion of
CD4+, CD8+ and sIGD+ cells. These showed monotypic
surface immunoglobulin light chain expression and high
levels of BCL-2 protein expression on staining with the
monoclonal antibody bc12/100. The cells remained viable,
predominantly in GO/GI phase, for at least 48 hours at 37°C.
Presentation of CD 40 antibody on a monolayer of Ltk- cells
transfected with the IgG (Fc) receptor II in the presence of
interleukin 4 (IL4) stimulated cell division within 48 hours
with increase of the S/G2 fraction measured by propidium
iodide staining and flow cytometry. Thereafter prolonged
culture was possible with the cells developing plasmacytoid
cytology but losing surface CD 38 expression, suggesting
differentiation to a resting B-cell phenotype. Cytogenetic and
polymerase chain reaction studies confirmed the persistance
of clones bearing the t(I4;18) chromosomal rearrangement
during culture. In contrast, BCL-2 negative germinal centre
cells from six benign hyperplastic tonsils showed extensive
apoptotic cell death when isolated at 37°C for 24 hours. The
germinal centre cells could also be stimulated to proliferation
with CD 40 antibody and IL4, showing similar cell cycle
kinetics to the lymphoma cells.
These findings confirm resistance to apoptosis as a feature
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that increased BCL-2 expression exerts an oncogenic effect in
this manner. It does not however appear to influence the
proliferative capacity of the cells in the CD 40 culture
system.
3 Effect of tumour necrosis factor (TNF) a on four human
cervical cancer cell lines
J.S. Beesley, W.P. Soutter & J.O. White
Royal Postgraduate Medical School, Institute of Obstetrics
and Gynaecology, Hammersmith Hospital, Du Cane Road,
London W12 ONN, UK.
TNFa has been shown to be cytotoxic to several transformed
cell lines. In the present study we have investigated its effect
on four human cervical cancer cell lines - HeLa, Sitta, C33-A
and HOG-1. Cells were cultured in Phenol Red-free DME/
F12 medium +2% DCCFCS ± TNFa for 4 days. TNFa
inhibited HOG-1 proliferation, determined by both cell
counting and DNA content, in a dose dependent manner and
at 10 ng/ml caused a maximum inhibition of 50%. However
TNFa only caused a weak inhibition of HeLa cell growth
(15% at 10 ng/ml) and had no effect on Sitta or C33-A cells
even at 100 ng/ml. Inhibition of HOG-1 cell proliferation by
TNFa was blocked by 10 nM dexamethasone and suggested
that Phospholipase A2, which is inhibited by glucocorticoids,
could be involved in TNFa cellular signalling in these cells.
In a number of cell types TNFa has been shown to induce
programmed cell death (apoptosis) which is characterised by
endogenous endonuclease activation and subsequent DNA
strand breakage. Therefore in these experiments TNFa-
induced apoptosis of HOG-1 cells was demonstrated by run-
ning DNA extracted from treated cells on an agarose gel and
observing the characteristic laddering pattern of fragmented
DNA.
In conclusion, while it has been demonstrated that HOG-1
cells are sensitive to TNFa, it will be important to investigate
why other cervical cancer cell lines are resistant to it and
whether their cellular signalling pathways are altered.
4 Gene expression and cellular proliferation kinetics in 18
human in vitro cell lines
H. Warenius & P. Browning
CRC Oncology Research Unit, University of Liverpool,
Department of Medicine, UK.
We have examined the relationship between the products of
the p53 gene and c-myc and pan-ras proto-oncogenes and
cellular proliferation kinetic parameters measured by BrdU
incorporation in 18 human in vitro cell lines of different
histological origin. A wide range of potential doubling times
was apparent, varying between 10 and over 40 hours and the
duration of S-phase was from 6 to 20 hours.
A strong correlation between the labelling index and the
ploidy (as measured by the index of cell line DNA to that of
diploid cells) was seen in the 18 cell lines examined
(r = - 0.6272 p = 0.005). Cell lines with a lower ploidy had a
greater proportion of cells in S-phase and there was also a
correlation between the potential doubling time (Tpot) and
DNA ploidy (r = 0.582, p = 0.011). Thus cells with a lower
ploidy were observed to proliferate more rapidly than those
with a high ploidy.
Actin, topoisomerase II and c-raf-l gene products did not
show any correlation with cell cycle kinetic parameters.
Both c-myc (r = 0.4247, p = 0.078) and pan-ras (r = 0.42,
p = 0.08) showed correlations with the labelling index with
values close to significance. Combining c-myc and pan-ras,
however, did not increase the level of their correlation with
the labelling index suggesting that they were acting as
independent variables. C-myc levels also showed a correla-
tion with Tpot (r = - 0.4503, p = 0.06) and the duration of
S-phase (r = -0.459, p = 0.055) in that high c-myc levels
appeared to be associated with faster S-phase transit and a
faster doubling time. High p53 levels by contrast correlated
with slower S-phase transit times.
5 Initiation of DNA synthesis by nuclei from scrape-ruptured
quiescent mammalian cells in high speed supernatants of
Xenopus egg extracts
M. Hola, S. Castleden, A. O'Toole, M. Howard &
R.F. Brooks
Anatomy and Human Biology Group, Division of Biomedical
Sciences, King's College, Randall Institute, 26-29 Drury
Lane, London WC2B SRL, UK.
Demembranated sperm heads, detergent-isolated somatic
nuclei and even naked DNA are efficiently replicated in
cytoplasmic extracts of activated amphibian eggs, but only
after nuclear assembly and the formation of an intact nuclear
envelope.'-4 DNA synthesis has not previously been shown
to be initiated in high-speed (100,000g) supernatants of egg
cytoplasm because they do not contain the vesicular material
required to support nuclear envelope formation.3 Here we
show that mammalian nuclei prepared by scrape-lysis are
able to initiate DNA replication in such high-speed super-
natants. These nuclei being DNA synthesis asynchronously.
This asynchrony cannot be attributed to differences in the
time taken for nuclear assembly as previously supposed.'-2
Instead, we suggest that the asynchrony reflects intrinsic
differences between nuclei and that these differences are a
major cause of cell cycle variability. Our demonstration of
initiation in high-speed supernatants now enables the initia-
tion of eukaryotic DNA synthesis to be studied in the
absence of nuclear assembly.
1. Blow, J.J. & Laskey, R.A. Cell, 47, 577-587 (1986).
2. Blow, J.J. & Watson, J.V. EMBO J, 6, 1997-2002 (1987).
3. Sheehan, M.A., Mills, A.D., Sleeman, A.M., Lasky, R.A. & Blow,
J.J. J. Cell Biol., 106, 1-12 (1988).
4. Cox, L.S. & Leno, G.H. J. Cell Sci., 97, 177-184 (1990).
6 Histological subtypes of ductal carcinoma in situ correlate
with proliferative activity, hormone receptor status and oncop-
rotein expression.
L.G. Bobrow', L.C. Happerfield', R.J. Springall2 &
R.R. Millis2
'ICRF Immunohistology Unit, and 2ICRF Clinical Oncology
Unit, Guy's Hospital, London SE] 9RT, UK.
There is current interest in the biology of ductal carcinoma in
situ (DCIS) both because it is the earliest recognisable phase
of mammary carcinoma and as a possible guide to treatment
for the increasing number of cases now being detected in the
National Breast Cancer Screening programme. The his-
tological classification is currently based on ill defined archi-
tectural features. Correlation between biological markers, in-
cluding various proliferation indices, and histological pat-
terns have been demonstrated. Most studies, however, have
been small and have only looked at one or two markers. We
have examined 102 cases of pure DCIS using a carefully
defined classification based on cell morphology and his-
tological architecture and evaluated four biological markers
using immunohistochemistry. The results show strong cor-
relation between histological classification and all the
biological markers, as well as between the individual
markers. The most significant correlation with histological
subtype was found with the expression of the proliferation
antigen KiSl, followed respectively by the expression of pro-
gesterone receptor, c-erbB-2 oncoprotein and mutant p53
protein. These findings may be of significance in planning
future treatment protocols for DCIS.440 JOINT WINTER MEETING REPORT
7 Relationship between c-erbB-2 expression and cell pro-
liferation in human breast cancer
S.J. Oakes, P.D. Stanton & T.G. Cooke
Department of Surgery, Royal Infirmary, Glasgow, UK.
Overexpression of the c-erbB-2 oncoprotein has been shown
to adversely influence prognosis in human breast cancer. As a
growth factor receptor, it is possible that this effect is
mediated via increased cellular division. We have therefore
studied the relationship between c-erbB-2 expression and pro-
liferative activity of breast tumours.
Seventy-three women with breast cancer were given 200 mg
ofthe thymidine analogue bromodeoxyuridine (BUDR) 4-10
hours prior to surgery. Alcohol fixed tumour samples were
enzymatically disaggregated and stained for DNA content
and BUDR content. Multiparameter flow cytometry enabled
measurement of tumour ploidy, the proportion of cells in S
phase (labelling index, LI), length of S phase (Ts), and
potential doubling time (Tpot). Immunohistochemical
localisation of c-erbB-2 was carried out using the polyclonal
antipeptide antibody 21N and an avidin-biotin system.
Twenty-eight tumours (38%) were positive for c-erbB-2.
Thirty-two tumours (43%) were DNA diploid, and these
were significantly less likely to be c-erbB-2 positive than
DNA aneuploid tumours (x2 = 4.3, p = 0.04). Values of
kinetic parameters were compared in c-erbB-2 positive and
negative tumours using the Mann-Whitney statistic, with no
significant difference in respect of LI (p = 0.28), Ts (p = 0.82)
or Tpot (p = 0.51).
These data provide no evidence that expression of c-erb-2
provides a growth advantage in human breast cancer.
8 Expression of proliferating antigen (PCNA) in dysplasia of
the tracheobronchial epithelium
N. Pendleton', G.R. Dixon2, N.L. Occleston', H.E. Burnett',
M.W. Myskow2 & J.A. Green'
'J.K. Douglas Laboratories, Clatterbridge Hospital, Bebington,
Wirral and 2Histopathology Department, Broadgreen Hospital,
Liverpool, UK.
Dysplasia of the tracheobronchial epithelium is considered a
preneoplastic lesion. Proliferating cell nuclear antigen
(PCNA) is expressed in the nuclei ofcells in the cell cycle and
has been studied by other groups in lung carcinoma. Using
the immunocytochemical localisation of PCNA as a method
of measuring proliferation we have noted marked differences
in the expression of this antigen in normal and neoplastic
cells from the bronchial tree. Forty-seven cases of bronchial
dysplasia have been collected over the period 1981-1989 by
the Department of Histopathology at Broadgreen Hospital
and these were studied with a monoclonal antibody raised
against PCNA (PC10 DAKO) and compared with 32 cases
of normal bronchial epithelium from a main bronchus. All
cases have been reviewed and classified as a mild, moderate
and severe. Out of the 47 cases, three showed mild dysplasia,
11 moderate dysplasia, 33 severe dysplasia. In each case a
minimum of 100 nuclei per section were counted and the
results expressed as percentage of positive nuclei. A two-
tailed Mann-Whitney test was performed comparing the
results from normal bronchus to those of each group of
dysplasia which showed no difference in the percentage of
positive cells in mild dysplasia (P>0.1) but significant in-
crease in the PCNA expression in moderate dysplasia
(P = 0.01) and severe dysplasia (P<0.001). The mitotic
indices of the dysplastic biopsies showed a significant correla-
tion with the PCNA percentage (n = 47, r = 0.67, p =<0.00).
From these results we conclude that in moderate and severe
dysplasia there is a marked increase in the number of cells
with proliferating cell nuclear antigen and presumably cycling
cells. This may indicate that in moderate and severe dysplasia
the normal mechanisms of growth control have been lost.
9 Uptake of radiolabelled amino acids in experimental rat
tumours: influence of blood flow and tumour growth rate
P. Carnochan', B.J. Deehan', M. Trivedi', A.J. Tombs2,
J. Sandle2 & R.J. Ott'
'Joint Department of Physics, 2lmmunology Section, Institute
of Cancer Research, Royal Cancer Hospital, 15 Cotswold
Road, Belmont, Sutton, Surrey SM2 SNG, UK.
Radiolabelled amino acids combined with Positron Emission
Tomography (PET) show promise for the accurate delinea-
tion of viable extent and may also provide a rapid and
sensitive indicator of response to therapy. Promising early
clinical reports led us to investigate the potential use of the
amino acid analogue L-3-iodo-x-methyl tyrosine (IMT),
which may be radioiodinated with isotopes suitable for PET
or conventional single photon imaging. We have studied the
biodistribution and kinetics of ['25I]IMT using two transplan-
table tumour systems in hooded rats, and compared the
findings with those using the natural amino acid L-tyrosine
(TYR) radiolabelled with tritium.
Preliminary studies using HSN tumours demonstrated
maximum tumour uptake of IMT (0.85 ± 0.093% dose/gm,
mean ± 1 s.d.) at 15 minutes post iv infusion and prolonged
retention in tumour relative to normal brain tissue (TNRI5mm,,
= 2.39 ± 0.21, TNR24hr = 7.43 ± 0.76). Brain uptake of IMT
was found to be significantly reduced by competition with
another large neutral amino acid phenylalanine, however,
relatively less effect was seen in tumour and no change in
IMT uptake was observed in skeletal muscle. Quantitative
autoradiography revealed sharp delineation of the tumour
boundary, and uniform IMT uptake was found even in
poorly vascularised tumour regions, as confirmed by endo-
thelial immunohistochemistry. IMT was found not to be
incorporated into proteins.
Similar levels of IMT uptake were found using OES.HR1
tumours (Smith, T.A.D. et al., Br. J. Cancer, 1991, 64, p821)
during growth stimulated by exogenous oestrogen. Following
tumour growth arrest by removal of the oestrogen stimulus
IMT uptake was seen to fall from 1.72 ± 0.42% to 1.00 +
0.39% dose/gm, however this was matched by a fall in
tumour blood flow as estimated by 99"Tc-HMPAO distribu-
tion (1.07 ± 0.43% to 0.60 ± 0.33% dose/gm). Comparative
studies using TYR also showed decreased radiotracer uptake
in OES.HR1 tumours after growth arrest (0.87 ± 0.20 to
0.73 ± 0.16% dose/gm), and was associated with a similar
reduction in 9'9Tc-HMPAO uptake (0.84 ± 0.17 to 0.57 +
0.13% dose/gm). Unlike IMT however, a substantial propor-
tion of TYR uptake in tumours was found to be protein
bound (51 ± 19%), with a reduced but significant level of
incorporation being seen following tumour growth arrest
(30 ± 15%).
We conclude that IMT kinetics are more strongly
influenced by blood flow and diffusion than cell proliferation,
and that these factors are also of significance when using
radiolabelled natural amino acids. Our findings suggest that
the clearance of non-bound radiotracer from tumours is
likely to be slow, and may be beyond the limits of observa-
tion for short-lived radionuclides such as "C (t,1/2 = 20 mins)
commonly used for clinical PET imaging.
10 Investigation of mutation and expression of the p53 gene
in non-Hodgkin's lymphomas
M.C.M. Finneganl, K.A. Lee', D.W. Hammond', J.R.
Geopel2, B.W. Hancock' & M.H. Goyns'
'Department of Clinical Oncology, Royal Hallamshire Hos-
pital, Sheffield S1O 2JF and 2Department of Pathology, Wes-
ton Park Hospital, Sheffield SJO 25J, UK.
The presence of altered forms of the p53 tumour suppressor
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change in human malignancy. The occurrence of missense
mutations in this gene lead to the synthesis of abnormal
forms ofits protein product. The latter are much more stable
than the wild-type p53 protein, and can be readily detected
by immunohistochemistry. Recent reports have demonstrated
that 30% of high grade, and 10% of low grade non-
Hodgkin's lymphomas (NHL), show positive staining for
p53, and thus suggest that mutations of p53 are relatively
common in NHL, especially in high grade NHL.
We have studied the p53 gene in a series of non-malignant
hyperplastic reactive nodes, low grade NHL and high grade
NHL. It had previously been observed in solid tumours that
mutations in one allele of the p53 gene were often accom-
panied by the loss of the other allele, as indicated by
monosomy of chromosome 17. In our series of NHL we
found that very few NHL samples (>10%) had lost a copy
of chromosome 17. We decided, however, to examine p53 for
the presence of mutations, and used the technique of
chemical mismatch cleavage (which should allow all muta-
tions to be identified). PCR products representing exons 2-4,
5-6, 7-9 of the p53 gene were prepared from the lymph
node biopsy samples, and then subjected to mismatch
cleavage. We found that only 1/22 NHL samples exhibited a
mutation, which indicated that point mutations ofp53 might
not be common events. Southern blot analysis of 30 NHL
samples also failed to reveal evidence for any rearrangements
or deletions of this gene. However, Northern blot analysis
demonstrated that, whereas it was not possible to detect p53
mRNA in reactive hyperplastic nodes, 11/25 NHL samples
showed clear expression ofp53. It is possible that the positive
immunohistochemical staining that is seen in NHL is the
result of overproduction ofwild type p53 protein. This might
indicate that an alternative mechanism for p53 inactivation is
operating in NHL cells; possibly involving the stabilisation of
the p53 protein by a target protein, such as MDM2.
This work was supported by the Yorkshire Cancer
Research Campaign.
11 Altered p53 levels in cisplatin-resistant ovarian cell lines
R. Brown', A. Edlin', P. Burns2, C. Clugston' & B. Vojtesek3
'CRC Department Medical Oncology, Beatson Laboratories,
Glasgow G61 IBD; 2CRC Beatson Laboratories, Glasgow G6J
IBD; 'CRC Laboratories, University ofDundee, Dundee, UK.
Levels of p53 protein were measured by Western and ELISA
analysis using p53-specific monoclonal antibodies in human
ovarian cell lines resistant to the chemotherapeutic drug cisp-
latin. Resistant mutants that had been isolated by a single
exposure of the ovarian cell line A2780 to 15 laM cisplatin
followed by prolonged growth in non-selective conditions
(McLaughlin, et al., 1991, Cancer Res., 51, 2242-2245) and
cell lines selected by chronic exposure to cisplatin were com-
pared to their respective sensitive parental cell lines. 6/12
independent single-step mutants had elevated p53 levels com-
pared to non-selected A2780 clones. 2/5 of chronically
selected cisplatin resistant ovarian lines had elevated p53
levels. Immunoprecipitation of extracts with mutant p53-
specific antibodies and direct PCR sequencing of cDNA
suggest that this increased p53 is not due to p53 mutations in
the resistant lines. Similarly, transfection and expression of a
mutant p53 in the sensitive parental line, A2780, does not
confer cisplatin resistance or an increase in the frequency of
cisplatin resistant mutants occurring in the cell population.
However, low doses of cisplatin does induce p53 levels and
since this induction has a more prolonged time-course in
resistant cells, we suggest that it is the altered induction or
stability of the protein that influences response to cisplatin.
Studies are underway to examine if inducing p53 can confer
resistance and if this affects cell-cycle progression in the
different cell lines.
12 Immunohistochemical detection of p53 protein as a prog-
nostic marker in mammary carcinoma
D.M. Barnes', E.A. Dublin2, C.J. Fisher', D.A. Levison2 &
R.R. Millis'
'ICRF Clinical Oncology Unit and 2Department of Histo-
pathology, UMDS, Guy's Hospital, London, UK.
An immunohistochemical study for p53 has been carried out
on 195 primary breast cancer patients, with a 10-year median
follow-up. Anti-p53 polyclonal antibody CM-1 has been used
with a peroxidase conjugated streptavidin biotin technique on
formalin fixed paraffin embedded sections. The presence of
p53 protein was indicated by positive staining of the tumour
nuclei. In this pilot study it was found that patients with
carcinomas which expressed p53 protein in the majority of
their tumour cells (19% of cases) had a considerably worse
prognosis than those who did not. The effect of the presence
of the protein is seen on disease free interval, overall survival
and survival after relapse and is seen in node negative, as
well as node positive, patients. Furthermore, the effect is
most apparent in patients with infiltrating lobular and grade
II infiltrating ductal carcinomas who have a rather
heterogeneous clinical behaviour and are difficult to sub-
divide on the basis of currently available markers. Cox mul-
tivariate analysis shows that p53 majority staining is second
only to node status in significance of effect on overall sur-
vival.
13 pRB phosphorylation events in GlA are inhibited during
cell cycle arrest by a-IFN
N.S.B. Thomas & A. Bybee
Department of Haematology, UCMSM, 98 Chenies Mews,
London WCIE 6HX, UK.
The retinoblastoma protein, pRB, is multiply phosphorylated
in a cell cycle dependent manner and this is thought to
control cell cycle progression. Actively cycling human cells
contain partially phosphorylated pRB in early GI (GIA).
These intermediate forms of pRB become further phos-
phorylated as cells pass into late GI (GIB). In contrast, cell
cycle arrest of a human B-cell line (Daudi) by m-IFN results
in an accumulation of cells in GI and these cells contain the
hypo-phosphorylated form of pRB in both GIA and GIB.
Hypo-phosphorylated pRB is detectable in GI within 2-4 h
of m-IFN addition, but not in other cell cycle phases even
though other events stimulated by a-IFN, such as a decrease
in c-myc protein levels or induction of the DAI kinase, are
not restricted to GI. Since hypo-phosphorylated pRB is
thought to prevent cell proliferation, cell cycle arrest induced
by x-IFN may be mediated by preventing the initial phos-
phorylation of pRB during or prior to GIA ac-IFN does not
increase phosphate turnover on pRB, therefore the decrease
in pRB phosphorylation is probably due to decreased kinase
activity. One candidate pRB kinase is p34`/c2Ip58zYcl`n. The
phosphorylation of p34cdC2 and its kinase activity against a
pRB peptide is inhibited by ax-IFN. Further, a-IFN inhibits
pS8CYChDA synthesis. In cycling cells p58CyChnA synthesis occurs
during GIB/early S phase, coincident with the phosphoryla-
tion ofp34cdc2 Thus, p34'c2/p58cYcI` probably does not cause
the initial, partial phosphorylation ofpRB in GIA, so at least
one other unidentified a-IFN-sensitive kinase is needed to
'prime' the phosphorylation of pRB in GIA-
Supported by the CRC and Kay Kendall Leukaemia
Fund.
14 Loss of tumour suppressor genes in prostatic cancer
S.M. Phillips, D. Morton', S.J. Lee2, D.M. Wallace & J.P.
Neoptolemos'442 JOINT WINTER MEETING REPORT
Departments of Urology and 2Pathology, Queen Elizabeth
Hospital, Birmingham B15 2TH; and 'Academic Surgery Unit,
Dudley Road Hospital, Birmingham B18 7QH, UK.
In the UK prostatic cancer accounts for 3% of all deaths in
men. Inactivation of tumour suppressor genes is thought to
be important in human cancer but very little is known about
prostatic cancer. Paired tumour and leucocytes were obtained
from 21 men undergoing transurethral resection or obstruc-
tive prostate cancer (T2, MO = 4; T2, MI = 2; T3, MO = 5;
T3, MI = 5; T4, MO = 1; MI = 4). Loss of heterozygosity
was determined by Southern blotting using polymorphic pro-
bes in regions of known or suspected tumour suppressor
genes.
No deletions were found in chromosome 16p in 16 infor-
mative cases. Probing of the RB gene locus revealed three
deletions in eight informative cases and three out of seven
informative cases using probe EF544 which is close to the
APC and MCC loci (x227 revealed no deleteions). Using
three probes for chromosome lOp-q (CTBO7, EFD75 and
D10590) four, three and five deletions were found in 11, 14
and 15 informative cases respectively.
In conclusion these results implicate the RB and APC
genes along with a putative suppressor gene (or genes) on
chromosome 10 in prostatic carcinogenesis.
15 Role of transferrin receptor in estrogen modulated growth
regulation in primary breast cancer
V. Makinde', S. Dilly', C. Corbishley, S. Lowndes, J. Quil-
liam, R. Sutcliffe, H. Ford & J.-C. Gazet
Breast Research Unit and 'Histopathology Department, St
George's Hospital, London SW17 OQT, UK.
The receptor for the iron transport protein transferrin, is
commonly expressed on the cells of human carcinoma includ-
ing breast cancer and breast cancer cell lines. As iron is an
essential element of oxidative respiratory enzymes, cells in an
actively dividing state require it's incorporation. Growth
regulation of breast cancer cells is influenced by estrogen and
to a lesser extent, by progesterone. Therefore the present
study has examined primary breast tumours for the expres-
sion of transferring receptors (TR), estrogen receptor (ER),
progesterone receptor (PgR) and epidermal growth factor
receptor (EGFR), to see whether TR expression correlated
with markers suggesting good growth control (ER, PgR) or
with a marker (EGFR) associated with poorly differentiated
tumours. Immunocytochemical staining was performed on
114 patients 72 of which were postmenopausal and 42 were
premenopausal. Our results show a strong correlation
between the expression of TR and ER (p<0.004) and
between TR and PgR (p<0.002), irrespective of the
menopause status. There were no significant correlations
between EGFR with either TR or ER. The results suggest a
possible relationship between TR expression and estrogen
mediated growth regulation. For this reason TR may well be
a favourable prognostic marker for predicting response to
endocrine therapy in addition to its role as a marker for cell
proliferation.
16 The expression of transforming growth factor-B isoforms
in human breast cancers
J. MacCallum', J.C. Keen2, J.M.S. Bartlett2, A.M. Thomp-
son', W.R. Miller2 & J.M. Dixon'
'Department of Surgery, Royal Infirmary and 2ICRF Unit of
Medical Oncology, Western General Hospital, Edinburgh, UK.
Transforming growth factor (TGF)-ps are a group of
regulatory proteins which have in common the ability to
transform fibroblasts. In addition, they may have effects on
epithelial cell proliferation and it has been proposed that
some effects of tamoxifen on human breast cancers may be
mediated by induction of the expression of the TGFI3s. Three
closely-related members of the TGFP family, TGFPI, TGFP2
and TGFPI3 have been identified and the biological activity of
these three isoforms may differ. The aim of the present study
was to assess whether messenger RNA for the three isoforms
of TGFPi could be identified in a series of human breast
cancers.
Twenty-four human breast cancers have been studied using
RNAase protection assay and specific riboprobes for TGFPi,
TGFP2 and TGFP3. Tumours were considered positive for
specific RNA expression if bands were identified on
autoradiography with molecular weights corresponding to
the appropriate full-length transcript. Of the 24 breast
cancers, 22 (92%) expressed TGFPI, 16 (67%) TGFPi2 and 21
(88%) expressed TGFP33. Sixteen cancers expressed all three
isoforms, six expressed one or two of the isoforms (the
patterns were different in each of the six) and two cancers did
not express any of the TGFPI isoforms although in these two
cancers the control y actin riboprobe was positive. This study
is the first to report on the presence of the TGFP isoforms in
human breast cancer. It provides a basis to assess the clinical
significance of patterns of TGFP isoform expression and will
allow any changes induced by tamoxifen treatment to be
investigated.
17 Expression of MRNA for bFGF in human breast cancers
and breast cancer cel lines
J.H.R. Winstanley, S. Anandappa, D. Fernig, S.J. Leinster,
P.S. Rudland & B.R. Barraclough
Departments ofSurgery and Biochemistry, University ofLiver-
pool, Liverpool, UK.
It has been suggested that basic fibroblast growth factor
(bFGF) is expressed during the growth and development of
the normal mammary gland. In addition since bFGF is also
a potent angiogenic factor it may play a role in the develop-
ment of invasive breast cancers. We have therefore investi-
gated the expression of messenger RNA (mRNA) for bFGF
in 17 benign breast lesions, 111 invasive carcinomas and in
four human malignant breast epithelial cell lines.
Messenger RNA was extracted from snap-frozen biopsy
specimens and cell lines by standard methods. Relative levels
of bFGF mRNA expression were determined using Northern
hybridisation and scanning densitometry. Sixteen (94%) of
the benign and 78 (70%) of the malignant lesions had detect-
able levels of bFGF mRNA (Chi-square p = <0.02). The
mean and median levels of expression relative to a consti-
tutively expressed marker mRNA were 2 and 5 fold greater
in benign than malignant lesions respectively (Mann-Whitney
U test p = 0.001). Preliminary analysis indicates that bFGF
mRNA expression is not related to either tumour size or
nodal status. In the malignant cell lines bFGF mRNA and
bFGF itself was expressed in two out of four lines examined.
Although there is a significant decrease in the average level
of bFGF mRNA expression in malignant compared with
benign breast lesions, its expression is maintained in a sub-
group of patients similar to its expression in a subgroup of
malignant cell lines. Our results therefore suggest the possibi-
lity that bFGF may contribute to the development of inva-
sive carcinomas but only in a restricted group of patients.
18 Caffageenans: novel, selective growth factor antagonists
with anti-proliferative activity
R. Hoffman' & D. Paper2
'Clinical Oncology and Radiotherapeutics Unit, MRC Centre,
Hills Road, Cambridge CB2 2QH, UK; 2Institute for Phar-
macy, University of Regensburg, Universitatstrasse 31, 8400
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We have exploited the observation that the polysulphated
carbohydrate heparin binds to some growth factors to iden-
tify new growth factor antagonists. The activities of com-
pounds were assessed by examining their abilities to reduce
the binding of radiolabelled growth factors to cells. From an
initial screening programme, carrageenans - polysulphated
carbohydrates isolated from red algae - were identified as
potent growth factor antagonists. All of the carrageenans
tested inhibited binding of basic fibroblast growth factor
(bFGF), platelet-derived growth factor (PDGF) and trans-
forming growth factor P1 (TGF,11) (which all bind to
heparin), but the carrageenans did not inhibit binding of
insulin-like growth factor 1 (IGF1) or transforming growth
factor oc( TGFa) (which do not bind to heparin). The most
potent carrageenans for inhibition of binding of bFGF,
PDGF and TGFP1 were t-carrageenan, K-carrageenan and
A-carrageenan respectively (IC50 values = 0.3, 0.5 and 15 ytg/
ml respectively). I-carrageenan inhibited the proliferation of
the FGF-dependent endothelial cell line FBHE as determined
in an MTT assay (IC50 approx. 3itg/ml) and also inhibited
the proliferation of some tumour cell lines. I-carrageenan is
of potential use as an anti-cancer agent by inhibiting both
autocrine stimulation of tumour cells and by inhibiting the
proliferation of capillary endothelial cells - a process
required for the neo-vascularisation of tumours.
19 Increased malignant cell adhesion to vascular endothelium
D.A. Browell, J.A. Kirby, B.K. Shenton & T.W.J. Lennard
Department of Surgery, The University of Newcastle upon
Tyne, NE2 4HH, UK.
Increasing adhesion of malignant cells to vascular endothe-
lium is likely to promote intravascular tumour spread and
metastasis. We have studied the effect of the supernatant
from cultured benign (renal epithelial cells) and malignant
(A549 and HT29) cell lines on binding of A549 and HT29 to
human umbilical vein endothelial cells (HUVEC). HUVEC
were cultured to confluence in a standard medium (Ml99
containing HEPES buffer endothelial growth cell supplement
and 20% (v/v) foetal calf serum). The HUVEC were then
cultured for 24 hr with standard media containing 5 or 10%
(v/v) supernatant from the benign or malignant cell lines,
before 5 x 104 51Cr labelled malignant cells were added for 10
minutes. The monolayers were washed, remaining adherent
cells were lysed with 1% Triton, the number of malignant
cells bound was judged by y-spectrometry. Results were sub-
jected to an analysis of variance. The A549 and HT29 cells
bound more avidly to the HUVEC pretreated with super-
natant from malignant cells than to the HUVEC with no
pretreatment or pretreatment with benign cell supernatant
(p<0.001). Immunofluorescent studies of the malignant cell
supernatant stimulated HUVEC revealed an upregulation of
ICAM-1, ELAM-1 and VCAM-1 following a similar period
of stimulation (p<0.001). This suggests that malignant cells
may exert a paracrine effect upon endothelial cells in such a
way as to promote malignant cell adhesion and promote the
development of metastasis.
20 Proliferating cells in human colorectal tumours express
the CD44 adhesion molecule
A.M. Abbasi', K.A. Chester', I.C. Talbot2, G. Boxer' &
R.H.J. Begent'
'CRC Laboratories, Department of Clinical Oncology, Royal
Free Hospital School ofMedicine, London NW3 2PF and 2St.
Marks Hospital and ICRF Colorectal Unit, London ECIV
2PS, UK.
CD44 is an integral membrane protein originally defined by
monoclonal antibody F1O-44-2 as a glycoprotein surface
marker of human T lymphocytes [Dalchau et al., 1980, Eur.
J. Immunol., 10, 745]. At least two distinct functions of CD44
are known. In leucocytes, CD44 is involved in adhesion to
high endothelial cells and homing to peripheral lymphoid
organs. In epithelial cells CD44 mediates anchorage to hyal-
uronate in basement membranes. The diverse range of func-
tions associated with CD44 have been partly explained by
cDNA sequence data showing that CD44 exists in several
different forms, obtained from the same gene by variations in
splicing.
Some forms of CD44 have been shown to confer metasta-
tic potential in experimental models [Hofmann et al., 1991,
Cancer Res., 51, 5292; Birch et al., 1991, Cancer Res., 51,
6660] possibly by mimicking lymphocyte behaviour [Arch et
al., 1992, Science, 257, 682]. In normal epithelial cells and
CD44 transfected 3T3 cells, however, CD44 expression has
been linked to proliferation [Alho & Urnderhill, 1989, J. Cell
Biol., 108, 1557; Flanagan et al., 1989, Immunology, 67, 167].
We asked whether the expression of CD44 in human cancer
was also linked to proliferation.
Flash frozen biopsies were obtained from surgical speci-
mens to three adenomatous polyps and 22 colorectal
adenocarcinomas (19 primary and 3 metastatic). CD44 was
detected by immunocytochemistry using monoclonal anti-
body F10-44-2, and proliferative areas defined by immuno-
cytochemistry using Ki-67 monoclonal antibody [Gerdes et
al., 1982, Int. J. Cancer, 31, 13] on serial sections.
Results showed that in normal colonic mucosa CD44 was
expressed on proliferating cells in the lower third of the
epithelial crypt. In tumours CD44 expression was consis-
tently associated with proliferative areas irrespective of
tumour stage of differentiation. Non-proliferating areas of
the carcinomatous epithelium did not express CD44. There
was no apparent association with tumour progression and
non-malignant tumours were strongly positive.
CD44 was only associated with proliferation of epithelial
cells. Stromal cells in the lamina propria and in the tumours
often expressed CD44 but did not appear to be proliferating
as defined by Ki-67. This is consistent with observations that
the CD44 cell adhesion molecule has distinct functions in
different tissues.
Our work demonstrates that F10-44-2 defined CD44 is
consistently expressed during proliferation by normal colo-
rectal epithelial cells, non-malignant colorectal tumour cells
and colorectal carcinoma cells.
21 Activity of type IV coliagenase in benign and malignant
breast disease
D.W. Miles', B. Davies2, L.C. Happerfield', L.G. Bobrowl,
R.D. Rubens' & F.R. Balkwill2
'ICRF COU, Guy's Hospital and 2ICRF, LIF, London, UK.
Invasive carcinoma of the breast is associated with variable
loss of basement membrane, of which a major component is
type IV collagen. We have localised mRNA and protein
expression of the 72 kDa and 92 kDa type IV collagenases
using in situ hybridisation and immunohistochemistry.
Enzyme expression was predominantly stromal and probably
associated with macrophages and fibroblasts. Myoepithelial
staining was also noted. Zymography allows the quantifica-
tion of the active and inactive forms of the different molec-
ular weight type IV collagenases. We have examined 11
samples of normal/benign breast tissue and 33 cases of
primary breast cancer. Although there was no significant
difference in the total amount of 72 + 62 kDa activity in
primary breast cancer compared with benign disease (27.6 U
v 30.1 U), there was significantly less of the inactive (72 kDa)
form in primary tumours 14.04 U v 22.88 U (p = 0.02). Con-
versely the mean amount of the active 62 kDa form was
higher in malignant compared to benign disease, though this
did not reach standard levels of statistical significance
(13.6 U v 7.2 U, p = 0.06). The ratio of active to total444 JOINT WINTER MEETING REPORT
72 kDa type IV collagenase was higher in primary breast
cancer (0.45 v 0.20, p = 0.003) and this ratio correlated with
tumour grade (test for trend p<0.0001). The 92/81 kDa
form of the enyzme was found predominantly in grade III
tumours with levels in this group being significantly higher
than in grade II or grade I tumours (32.3 U v 6.8 U v 1.3 U,
p = 0.03 & 0.02, respectively). Our data suggest that in
primary breast cancer a greater proportion of the 72/62 kDa
enzyme is in the active form and that 92/81 kDa activity is
associated with high grade tumours.
22 Serum metalioproteinases in prostate cancer
H. Wasan2, T. Baker', S. Tickle', A. Docherty', J. Flanders2
& J. Waxman2
'Celltech Limited and 'Oncology, Hammersmith Hospital,
London, UK.
The maxtix metalloproteinases (MMP) have roles in the
maintenance of the cellular supporting stroma and in tissue
invasion, angiogenesis and metastasis. Novel immunoassays
for the detection of interstitial collagenase, stromelysin and
tissue inhibitor of metalloproteinase 1 (TIMP 1) have been
developed. Levels in 36 patients with prostatic cancer were
compared with 57 age matched normal controls and 25
patients with rheumatoid arthritis. There were highly signi-
ficant differences in serum interstitial collagenase and TIMP-
1 levels between cancer patients and normal controls (P<
0.0001) and between 19 patients with metastatic disease com-
pared to 19 without (P<0.022). Levels at one year were
significantly different in those treated cancer patients in
remission versus those progressing (P<0.0399). Serum stro-
melysin levels were higher in rheumatoid arthritis as com-
pared to cancer patients (P<0.0001), and to normal controls
(P<0.0001). Pre-therapy serum TIMP-1 levels predicated
patient response at 12 months, as effectively as serum prosta-
tic acid phosphatase. This study provides a basis for the
introduction of metalloproteinase inhibitors in the treatment
of malignancy.
23 Over-expression of metallothionein in malignant melanoma
V.K. Shukla', P. Laidler', K. Horgan', L.E. Hughes', M.E.
Elms2, K.W. Schmid3 & B. Jasani2
Departments of'Surgery, 'Pathology, University of Wales Col-
lege of Medicine, Cardiff, U.K. and 3University of Munster,
Munster, Germany.
Metallothioneins (MTs) the ubiquitously expressed low mole-
cular weight proteins with high affinity for heavy metal ions
(e.g. zinc, copper, cadmium). MT over-expression in cancer
cell lines has been associated with resistance to anticancer
drugs and irradiation therapy. Attempts have been made to
relate immunohistochemically detectable MT to tumour
grade and its tendency to recur. Using a monoclonal anti-
MT antibody, E9, we investigated in a retrospective study the
MT profile of melanoma.
Paraffin-embedded, formalin fixed tissues were studied
from 48 patients with melanoma using standard two step
indirect immuno-peroxidase method. The cases comprised 43
superficial spreading melanoma (SSM) and five nodular
melanoma (NM) in which the thickness of the tumours was
0.0 to 1.5 mm. The presence of MT was observed in 15 of 43
SSM and all 5 NM (P<0.002). Exposed regions (calf, arm)
tended to show MT expression (15/28) more often than other
regions (trunk 5/20) (P<0.002). Melanomas less than
0.8 mm in thickness (i.e. with very low potential for metas-
tasis) expressed MT in 29% as compared to 65% in melan-
omas thicker than 0.8 mm (P<0.002). This study suggests
that MT expression is associated with potential for disease
progression and thus might be used as a prognostic indicator.
25 Regulation of polyamine acetylation by doxorubicin in
human breast cancer cells
D.M. Quick & H.M. Wallace
Departments of Medicine and Therapeutics and Biomedical
Sciences, University of Aberdeen, Aberdeen AB9 2ZD, UK.
The naturally occurring polyamines are essential for cell
growth and differentiation. They are found in high concen-
trations in rapidly growing and cancer cells and intracellular
concentrations correlate with cell growth rates, as growth is
decreased so polyamine content falls and vice versa. Indeed
recent evidence suggests that loss of polyamines precedes any
inhibition of growth implying a causal role for polyamines in
preventing growth. The polyamine content of the cell is
decreased by the interconversion of the higher polyamines to
either monoacetyl derivatives or smaller amines carrying less
charge, a process which may facilitate their excretion. In this
study we have investigated the link between growth inhibi-
tion and polyamine acetylation, the first step in the inter-
conversion pathway, in a human breast carcinoma cell line
using the commonly used anticancer drug, doxorubicin
(DOX), to limit cell growth.
T47-D cells were grown under standard cell culture condi-
tions in Dulbecco's medium supplemented with 10% (v/v)
foetal calf serum and insulin (8pg/ml). Polyamine inter-
conversion was measured as spermidine/spermine N-acetyl-
transferase (SAT) activity. Cell growth was measured as the
change in protein content and polyamines were quantified by
hplc.
DOX inhibited the growth of T47-D cells with an ID5, of
about 1 JiM. Inhibition of growth was accompanied by a
decrease of intracellular polyamine content. Cytosolic SAT
activity increased after DOX treatment with the increase
being almost exclusively an induction of the N'-SAT, the
enzyme responsible for the acetylation of spermine and sper-
midine in the N' position. Previous reports have shown
similar increases in N'-SAT activity in response to treatment
with polyamine analogues however unlike these inducers
DOX did not prolong significantly the half-life of the
enzyme. DOX itself had no effect on SAT activity when
added directly to the in vitro assay.
The depletion of cellular polyamines by DOX is due to
enhanced acetylation resulting in further degradation and/or
excretion. It may be that stimulation of polyamine cata-
bolism, and in particular N1-SAT activity, is an early event in
the cellular response to growth limitation by this and other
cytotoxic drugs.
26 Inhibition of the clonogenic growth of breast cancer cells
by tamoxifen and the novel steroidal antioestrogen ICI 182780
D.J. De Friend', J. Bell2, D. Wilkes3, E. Anderson2, C. West3
& A. Howell'
Departments of'Medical Oncology, 'Tumour Biochemistry and
3Radiobiology, Christie Hospital and Paterson Institute, Man-
chester M20 9BX, UK.
Antioestrogen therapy using tamoxifen has an established
role in the management of breast cancer. Although used as
an oestrogen antagonist, tamoxifen also exhibits intrinsic
partial agonist activity, which might potentially reduce its
clinical efficacy. ICI 182780 is a novel, steroidal antioestro-
gen, which is devoid of agonist activity and is currently
undergoing clinical trial. We have investigated the antioestro-
genic effects of 4-hydroxytamoxifen (Tam) and ICI 182780
(182) on MCF 7 breast cancer cells, using the Courtenay-
Mills clonogenic assay, which measures the ability of cancer
cells to grow as anchorage independant colonies in soft agar.
The standard assay was modified by the use of serum-free
media in order to optimise its sensitivity with respect to the
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Using this assay we were able to demonstrate a significant
increase in colony forming efficiency (CFE) in the presence of
a physiological concentration (1 nM) of Oestradiol (E2) com-
pared to control conditions. This oestrogenic stimulation was
inhibited by both ICI 182780 and 4-hydroxytamoxifen in a
dose dependant manner at concentrations between 10 nM and
1 gM. However, at the typical pharmacological concentration
of 1 JLM, ICI 182780 caused a significantly greater inhibition
of colony formation than 4-hydroxytamoxifen (p<0.001,
Student's t test).
Control E2 E2 + Tam E2 + 182
(I nM) (M nM) (IpM) (I nM) (IJM)
CFE (%) 0.374 0.648 0.07 0.007
We conclude that, in vitro, ICI 182780 produces a more
complete inhibition of the growth of oestrogen responsive
cells than 4-hydroxytamoxifen and may therefore offer poten-
tial therapeutic advantages in vivo for the treatment of
advanced breast cancer.
27 Roles of tumour necrosis factor and serotonin in the
antitumour action of the investigational anticancer agent 5,6-
dimethyl XAA
B.C. Baguley', G.L. Cole', L.-M. Ching', W.P. Joseph', L.L.
Thomsen', W.R. Wilson2, L. Zhuang' & L.J. Zwi2
'Cancer Research Laboratory and 2Section of Oncology,
University of Auckland Medical School, Auckland, New Zea-
land.
5,6-Dimethyl xanthenone-4-acetic acid (5,6-dimethyl XAA) is
a potent analogue of flavone acetic acid (FAA) and has been
accepted for potential clinical evaluation by the Cancer
Research Campaign, U.K. Like FAA, 5,6-dimethyl XAA
appears to exert its antitumour effects indirectly through the
stimulation of host responses. 5,6-dimethyl XAA, like FAA,
stimulated the release of tumour necrosis factor (TNF), as
detected using L-929 cells, and reduced blood flow in s.c.
colon 38 and in i.m. mammary MCa4 tumours. 5,6-dimethyl
XAA also stimulates nitric oxide formation, induces natural
killer activity and increases bone marrow colony forming
units in the mouse. These effects presumably all result from
secretion of cytokines. The question of whether 5,6-dimethyl
XAA stimulates formation ofTNF in humans was approach-
ed in vitro by comparing cultures ofmouse (J774) and human
(HL-60) macrophage lines. In both of these lines, 5,6-
dimethyl XAA stimulated the formation of larger amounts of
TNF mRNA than did FAA, and also stimulated at a lower
concentration. The question of whether 5,6-dimethyl XAA
induces tumour haemorrhagic necrosis through the action of
TNF was investigated by taking advantage of the observa-
tion that the serotonin antagonist cyproheptadine inhibits the
induction of tumour haemorrhagic necrosis by TNF. Co-
administration of cyproheptadine significantly inhibited both
the induction of tumour haemorrhagic necrosis and the prod-
uction of nitric oxide in response to 5,6-dimethyl XAA or
FAA. Reduction of plasma serotonin concentrations, by
pretreatment with reserpine and p-chlorophenylalanine, had a
similar but less pronounced effect. It is concluded that both
serotonin and TNF are important for the action of 5,6-
dimethyl XAA and related compounds.